RxDoctor Payments Data

Charles Curatalo, MD

Neurology · Santa Barbara, CANPI 1851345508

Payments from drug & device makers

$3,936in general payments, 2019–2025

Across 103 payments — averaging $38.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Harmony Biosciences LLC$259
  • Abbott$245
  • Jazz Pharmaceuticals Inc.$238
  • Biogen$202
  • Acadia Pharmaceuticals Inc$199
  • plus $1K from 13 others

What the payments were for

  • Food & beverage$3,919100%
  • Education$180%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$3,936 in reported general payments places this provider in the 60th percentile of 1,996 neurology providers in California.

See all neurology providers in California

Medicare billing

Part B allowed, 2024
$369,104
Medicare patients
782
Services billed
9,068

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XyremSodium Oxybate12$253,860
XywavSodium,calcium,mag,pot Oxybate11$220,089
WakixPitolisant Hcl12$168,519
Avonex Pen (4 Pack)Interferon Beta-1a11$89,359
Aimovig AutoinjectorErenumab-Aooe68$52,429
AptiomEslicarbazepine Acetate13$37,619
Nurtec OdtRimegepant Sulfate27$34,354
QuliptaAtogepant23$24,624
KeppraLevetiracetam12$17,870
Keppra XrLevetiracetam11$16,533
UbrelvyUbrogepant15$14,158
Emgality PenGalcanezumab-Gnlm21$14,074
NeuproRotigotine14$13,505
Lamictal XrLamotrigine12$10,859
Carbidopa-LevodopaCarbidopa/Levodopa155$6,576

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Harmony Biosciences LLCWakix$259$168,51912 claims
AbbVieQulipta, Ubrelvy$1,459$38,78238 claims
Sunovion Pharmaceuticals Inc.Aptiom$113$37,61913 claims
PfizerNurtec Odt$15$34,35427 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 1,996 neurology providers in California.

Other neurology in Santa Barbara

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →